# Phase 3 stomach cancer trials recruiting: 45 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 45 trials in phase 3 for stomach cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 stomach cancer trials: 45 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/stomach-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 45
- Recruiting or not yet: 45
- Read on: November 19, 2026

## Trials

The 25 newest of 45, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 14, 2026 | NCT07818070 | A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric... | Ono Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Gastric Cancer, Esophagogastric Junction Cancer, Esophageal Adenocarcinoma | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07818070) |
| August 27, 2026 | NCT07789184 | Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy | Sponsor not shown (see the record) | Phase 3 | Recruiting | Gastric Cancer, Peritoneal Metastasis | 170 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07789184) |
| July 14, 2026 | NCT07700979 | Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of... | Akeso | Phase 3 | Recruiting | Gastric / Gastroesophageal Junction Adenocarcinoma | 900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07700979) |
| April 8, 2026 | NCT07518147 | A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced... | Biokin (Shanghai) Biopharmaceutical Co., Ltd. | Phase 3 | Recruiting | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 438 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07518147) |
| March 23, 2026 | NCT07488611 | PROGAIN Trial in Gastric Cancer Surgery | Soonchunhyang University Hospital | Phase 3 | Recruiting | Stomach (Gastric) Cancer | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07488611) |
| February 24, 2026 | NCT07431281 | Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric... | AstraZeneca | Phase 3 | Recruiting | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer | 2,130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07431281) |
| January 26, 2026 | NCT07366528 | Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer | Ruijin Hospital | Phase 3 | Recruiting | Gastric Cancer (GC), Adjuvant Chemotherapy, Stage 3 Cancer, Docetaxel, Oxaliplatin | 387 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07366528) |
| January 12, 2026 | NCT07331454 | Robotic vs Laparoscopic Gastrectomy for cT4a Gastric Cancer | The First Affiliated Hospital with Nanjing Medical University | Phase 3 | Not yet recruiting | Gastric Cancer (GC) | 335 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07331454) |
| January 2, 2026 | NCT07315750 | A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without... | RemeGen Co., Ltd. | Phase 3 | Recruiting | Gastric Carcinoma | 555 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07315750) |
| January 2, 2026 | NCT07314203 | Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer | Fujian Medical University | Phase 3 | Not yet recruiting | Gastric Cancer, Surgery | 118 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07314203) |
| December 26, 2025 | NCT07304271 | Intraperitoneal Paclitaxel and Systemic Therapy Versus Systemic Therapy Alone in Gastric Cancer Patients With Peritoneal Metastasis | Sponsor not shown (see the record) | Phase 3 | Recruiting | Gastric Cancer Peritoneal Metastases | 262 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07304271) |
| October 16, 2025 | NCT07217704 | Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer. | SOFIE | Phase 3 | Recruiting | Esophageal Cancer, Gastric Cancer (GC), Gastroesophageal Junction | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07217704) |
| April 29, 2025 | NCT06949033 | Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced... | Sponsor not shown (see the record) | Phase 3 | Recruiting | Gastric Cancer (Including Stomach and Gastroesophageal Junction \[GEJ\]), Neoadjuvant Therapy, Adjuvant Chemotherapy, pCR... | 668 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06949033) |
| April 25, 2025 | NCT06944496 | A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low... | RemeGen Co., Ltd. | Phase 3 | Not yet recruiting | Gastric Carcinoma | 616 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06944496) |
| April 13, 2025 | NCT06925243 | Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for... | Sponsor not shown (see the record) | Phase 3 | Recruiting | Gastric Cancer (Including Stomach and Gastroesophageal Junction \[GEJ\]), Neoadjuvant Therapy, Adjuvant Chemotherapy, pCR... | 682 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06925243) |
| January 27, 2025 | NCT06793917 | Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable... | Fujian Cancer Hospital | Phase 3 | Recruiting | Gastric Cancer | 269 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06793917) |
| January 10, 2025 | NCT06768164 | Quality of Life After Billroth II or Roux-en-Y for Gastric Cancer | Assistance Publique - Hôpitaux de Paris | Phase 3 | Recruiting | Gastric (Cardia, Body) Cancer | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06768164) |
| January 1, 2025 | NCT06755554 | Investigation of Impact of Indocyanine Green on Volume of Lymphadenectomy in Resectable Gastric Cancer | Ukrainian Society of Clinical Oncology | Phase 3 | Recruiting | Gastric Cancer Stage II, Gastric Cancer Stage III, Gastric Cancer, Gastrectomy for Gastric Cancer | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06755554) |
| December 12, 2024 | NCT06731478 | Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction... | Daiichi Sankyo | Phase 3 | Recruiting | Gastric Cancer, Gastroesophageal Junction Cancer | 726 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06731478) |
| September 23, 2024 | NCT06608381 | Comparison Partial Versus Total Omentectomy in Minimal Invasive Distal Gastrectomy for cT3/4a Gastric Cancer (KLASS-10) | Gangnam Severance Hospital | Phase 3 | Recruiting | Gastric Cancer | 440 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06608381) |
| August 1, 2024 | NCT06532006 | A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and... | Shanghai Henlius Biotech | Phase 3 | Recruiting | Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer | 550 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06532006) |
| April 3, 2024 | NCT06346197 | Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas | Centre Leon Berard | Phase 3 | Recruiting | Gastric Cancer, MSI-H, Metastatic Cancer, Advanced Cancer | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06346197) |
| March 15, 2024 | NCT06313567 | Metronomic Capecitabine in Stage III Gastric Cancer | Fudan University | Phase 3 | Recruiting | Gastric Cancer | 722 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06313567) |
| March 6, 2024 | NCT06296706 | A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 3 | Recruiting | Gastric Cancer | 630 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06296706) |
| December 20, 2023 | NCT06177041 | M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS\<5, Locally... | FutureGen Biopharmaceutical (Beijing) Co., Ltd | Phase 3 | Recruiting | Locally Advanced Unresectable or Metastatic Gastric Cancer, Locally Advanced Unresectable or Metastatic... | 486 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06177041) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Fujian Medical University | 4 |
| Fudan University | 3 |
| [RemeGen Co., Ltd.](https://specstream.ai/data/clinical-trials/company/remegen-co-ltd) | 2 |
| Ruijin Hospital | 2 |
| Chinese University of Hong Kong | 1 |
| Fujian Cancer Hospital | 1 |
| Hallym University Medical Center | 1 |
| Gangnam Severance Hospital | 1 |
| Biokin (Shanghai) Biopharmaceutical Co., Ltd. | 1 |
| Asan Medical Center | 1 |
| Ottawa Hospital Research Institute | 1 |
| FutureGen Biopharmaceutical (Beijing) Co., Ltd | 1 |
| University of Dublin, Trinity College | 1 |
| [CSPC ZhongQi Pharmaceutical Technology Co., Ltd.](https://specstream.ai/data/clinical-trials/company/cspc-zhongqi-pharmaceutical-technology-co-ltd) | 1 |
| Transcenta Therapeutics (Hangzhou) Co., Ltd. | 1 |
| The Affiliated Hospital of Qingdao University | 1 |
| National Cancer Center, Korea | 1 |
| Centre Leon Berard | 1 |
| [Daiichi Sankyo](https://specstream.ai/data/clinical-trials/company/daiichi-sankyo) | 1 |
| Soonchunhyang University Hospital | 1 |
| [Jiangsu HengRui Medicine Co., Ltd.](https://specstream.ai/data/clinical-trials/company/jiangsu-hengrui-medicine-co-ltd) | 1 |
| [Akeso](https://specstream.ai/data/clinical-trials/company/akeso) | 1 |
| [Ono Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/ono-pharmaceutical-co-ltd) | 1 |
| The First Affiliated Hospital with Nanjing Medical University | 1 |
| SOFIE | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 26 |
| South Korea | 8 |
| Germany | 6 |
| Italy | 5 |
| Poland | 5 |
| United States | 5 |
| France | 4 |
| Canada | 3 |
| Australia | 3 |
| Brazil | 3 |
| Japan | 3 |
| Netherlands | 3 |
| Spain | 3 |
| Turkey (Türkiye) | 3 |
| Norway | 2 |
| Sweden | 2 |
| Argentina | 2 |
| Austria | 2 |
| Belgium | 2 |
| Chile | 2 |
| Romania | 2 |
| Taiwan | 2 |
| Thailand | 2 |
| United Kingdom | 2 |
| Vietnam | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Freight forwarders in the United States](https://specstream.ai/data/businesses/freight-forwarders/united-states)
- [Tiki bars in the United States](https://specstream.ai/data/businesses/tiki-bars/united-states)
- [Furniture rental companies in the United States](https://specstream.ai/data/businesses/furniture-rental-companies/united-states)
- [Tobacco companies in the United States](https://specstream.ai/data/businesses/tobacco-companies/united-states)
- [Gardening services in the United States](https://specstream.ai/data/businesses/gardening-services/united-states)
- [Towing companies in the United States](https://specstream.ai/data/businesses/towing-companies/united-states)
